Pooja A Chawla – författare

Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, schizophrenia, cerebral palsy, autism, ALS, and others.The book begins by presenting the foundations of drug delivery to the brain and addressing the associated challenges. It then delves into clinical trials and explores the future potential of the presented technologies.This reference is designed for drug delivery researchers in academia and corporations, providing them with the essential knowledge about overcoming the Brain-Blood Barrier and achieving targeted drug delivery to the central nervous system.

Consolidates current state of the art research into a single book volumePresents the challenges of drug delivery to the CNS in a comprehensive wayCovers the most relevant CNS conditions and diseasesProvides future perspectives and the most active research areas in this fast-moving field

Computational methods and understanding computational models are important in modern drug discovery. The book focuses on computational approaches that can improve the development of in silico methodologies. It includes lead hit methods, docking algorithms, computational chiral compounds, structure-based drug design, GROMACS and NAMD, structural genomics, toxicity prediction, enzyme inhibitors and peptidomimetic therapeutics

The book bridges the gap between pharmaceutics and molecular modelling at the micro, meso and macro scale. It covers Lipinski's rule of five, nanoparticulate drug delivery, computational prediction of drug solubility and ability to cross blood brain barrier, computer-based simulation of pharmacokinetic parameters, virtual screening of mucoadhesive polymers, QSPR modelling, designing of 2D nanomaterials and role of principal component analysis.

Rare diseases affect millions globally, yet patients often face delayed diagnoses, limited treatments, and insufficient support due to the conditions’ low prevalence and clinical complexity. This book, Revolutionizing Rare Disease Care: The Role of Artificial Intelligence and Machine Learning, addresses this unmet need by exploring how AI and ML technologies are transforming the diagnosis, treatment, and management of rare diseases. It offers a comprehensive, disease-specific analysis of AI-driven innovations in areas such as early detection, drug discovery, biomarker identification, and personalized therapeutic interventions. The book also examines ethical, regulatory, and implementation challenges, ensuring equitable and transparent integration of AI/ML in clinical practice. Covering rare diseases like amyloidosis, ALS, and choroideremia, the book presents real-world insights into how technology can revolutionize patient care. Timely and unique, this book is a vital resource for clinicians, researchers, data scientists, and healthcare policymakers seeking to harness AI/ML to improve outcomes and quality of life for patients with rare diseases.